4--1-tert.-butyl-piperidin | 17324-01-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4--1-tert.-butyl-piperidin
• 英文别名: 1-tert-butyl-4-(4-chloro-phenyl)-piperidine；1-Tert-butyl-4-(4-chlorophenyl)piperidine
• CAS: 17324-01-5
• 化学式: C₁₅H₂₂ClN
• 分子量: 251.799
• InChiKey: XFWLNCVCQMTERL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Arginase Inhibitors and Their Therapeutic Applications
  申请人：OncoArendi Therapeutics S.A.

  公开号：US20170319536A1

  公开（公告）日：2017-11-09

  Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.

  揭示了一种小分子治疗化合物，它们是较强的精氨酸酶1和精氨酸酶2活性抑制剂。还揭示了包含这些化合物的药物组合物，以及使用这些化合物治疗或预防与精氨酸酶活性相关的疾病或状况的方法。
• Heteroaryl sulfonamides and CCR2/CCR9
  申请人：ChemoCentryx, Inc.

  公开号：US10206912B2

  公开（公告）日：2019-02-19

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

  所提供的化合物是 CCR2 受体的强效拮抗剂。动物试验证明，这些化合物可用于治疗炎症，而炎症是 CCR2 的标志性疾病。这些化合物通常是芳基磺酰胺衍生物，可用于药物组合物、治疗 CCR2 介导的疾病的方法，以及用作鉴定 CCR2 拮抗剂的测定中的对照物。
• Arginase inhibitors and their therapeutic applications
  申请人：OncoArendi Therapeutics S.A.

  公开号：US10391077B2

  公开（公告）日：2019-08-27

  Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.

  所公开的小分子治疗化合物是精氨酸酶 1 和精氨酸酶 2 活性的强效抑制剂。还公开了包含这些化合物的药物组合物，以及使用这些化合物治疗或预防与精氨酸酶活性相关的疾病或病症的方法。
• HETEROARYL SULFONAMIDES AND CCR2/CCR9
  申请人：ChemoCentryx, Inc.

  公开号：US20170095458A1

  公开（公告）日：2017-04-06

  Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.